- Instrument
- Reagents and Kits
- Software
Multiplex Biomarker Imaging Market size was estimated at USD 561.2 Mn in 2021, growing at a CAGR of 12.1% during the forecast period 2022-2028. Increase in the adoption of the multiplex biomarker in immunology and oncology research, growing R&D investments by pharmaceutical and biotechnology companies, increase in demand for personalized medicine, and innovation of newer technologies in biomarker imaging are anticipated to fuel the multiplex biomarker imaging market size over the forecast period. Moreover, increase in preference for companion diagnostics and advantages of multiplex biomarker imaging over conventional methods are anticipated to boost the multiplex biomarker imaging market report over the forecast years. However, the high cost of the instruments, ethical issues of biomarker imaging techniques, and stringent regulatory policies are anticipated to impede the growth of market. Multiplex biomarker imaging is a technique carried to characterize and analyze the disease present in the body. Biomarkers are used in clinical studies to determine the diseases progress. Multiplex biomarkers have a major role in the medical industry and these are used in alone or combination to determine the characteristics and evaluate as an indicator of biological process. Multiplex biomarkers also help in the study of biological system by providing analysis to check the expression of various biomarkers. In August 2017, Quanterix launched high-sensitivity instrument Quanterix SR-Plex and assays for multiplex biomarker detection.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Multiplex biomarker imaging market expected to exhibit significant growth due to successful determination and validation of clinical data for various diseases related to cancer cells and immune cells. Majority of the market players are actively involved in the development of newer products and techniques to determine the disease progress. For instance, in December 2015, PerkinElmer, Inc. launched Vectra 3 system used to determine the deeper level analysis of disease mechanisms related to newer cancer immunotherapy approaches. Moreover, in September 2017, Aushon BioSystems and ABL, Inc. announced the adoption of Cira platform for ultrasensitive and multiplex biomarker analysis.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
[urltag url='request-table-of-content']